Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation

被引:4
作者
Mikulski, Damian [1 ,2 ]
Koscielny, Kacper [1 ]
Nowicki, Mateusz [2 ,3 ]
Wawrzyniak, Ewa [3 ]
Kalwas, Marta [4 ]
Kowalik, Monika [2 ]
Pryt, Mateusz [1 ]
Seczkowska, Emilia [5 ]
Swiatek, Agnieszka [6 ]
Wierzbowska, Agnieszka [2 ,3 ]
Fendler, Wojciech [1 ,7 ]
机构
[1] Med Univ Lodz, Dept Biostat & Translat Med, Lodz, Poland
[2] Copernicus Mem Hosp Lodz, Comprehens Canc Ctr & Traumatol, Dept Hematol, Lodz, Poland
[3] Med Univ Lodz, Dept Hematol, Lodz, Poland
[4] Med Univ Lodz, Dept Pathol, Chair Oncol, Lodz, Poland
[5] Polish Mothers Mem Hosp, Res Inst, Dept Anesthesiol & Intens Med Therapy, Lodz, Poland
[6] Clin Hosp Minist Interior & Adm, Dept Internal Med & Gastroenterol, Warsaw, Poland
[7] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
关键词
Autologous stem cell transplantation; multiple myeloma; neutrophil-to-lymphocyte ratio; plasma cell myeloma; INTERNATIONAL STAGING SYSTEM; PROGNOSTIC ROLE; RISK; DIAGNOSIS; CANCER; CRITERIA;
D O I
10.1080/10428194.2022.2136946
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-dose chemotherapy with autologous stem-cell transplantation (ASCT) remains the standard of care in multiple myeloma (MM) patients. This retrospective study aimed to assess the impact of neutrophil-to-lymphocyte ratio (NLR) and other complete blood count (CBC)-based predictors on PFS and OS of transplant-eligible MM patients. The CBC-based biomarkers were evaluated in a single-center cohort of 176 MM patients at three time points: at the diagnosis, the time of ASCT, and +100 d after ASCT. Univariable and multivariable Cox's regression analyses and Kaplan-Meier estimate were used in statistical analysis. NLR at ASCT (HR 1.15, 95% CI: 1.05-1.26) and hemoglobin at ASCT (HR 0.80, 95% CI: 0.68-0.94) were independent factors influencing PFS. In the model for OS, the only statistically significant factors were NLR at ASCT (HR 1.15, 95% CI: 1.04-1.27), bortezomib administration prior to ASCT (HR 0.52, 95% CI: 0.33-0.83) and age at diagnosis (HR 1.03, 95% CI: 1.00-1.06). NLR at ASCT is an independent predictive factor in MM patients undergoing ASCT.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 37 条
[1]   Statistics notes - The cost of dichotomising continuous variables [J].
Altman, DG ;
Royston, P .
BRITISH MEDICAL JOURNAL, 2006, 332 (7549) :1080-1080
[2]   Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses [J].
Austin, PC ;
Brunner, LJ .
STATISTICS IN MEDICINE, 2004, 23 (07) :1159-1178
[3]   Cancer-Related Inflammation [J].
Candido, Juliana ;
Hagemann, Thorsten .
JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 :S79-S84
[4]  
Chan Abigail Sy, 2020, J Clin Med Res, V12, P448, DOI [10.14740/jocmr4240, 10.14740/jocmr4240]
[5]   Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy [J].
Cho, Hyungwoo ;
Yoon, Dok Hyun ;
Lee, Jung Bok ;
Kim, Sung-Yong ;
Moon, Joon Ho ;
Do, Young Rok ;
Lee, Jae Hoon ;
Park, Yong ;
Lee, Ho Sup ;
Eom, Hyeon Seok ;
Shin, Ho-Jin ;
Min, Chang-Ki ;
Kim, Jin Seok ;
Jo, Jae-Cheol ;
Kang, Hye Jin ;
Mun, Yeung-Chul ;
Lee, Won Sik ;
Lee, Je-Jung ;
Suh, Cheolwon ;
Kim, Kihyun .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) :1280-1286
[6]   Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction A Systematic Review and Meta-analysis [J].
Dhakal, Binod ;
Szabo, Aniko ;
Chhabra, Saurabh ;
Hamadani, Mehdi ;
D'Souza, Anita ;
Usmani, Saad Z. ;
Sieracki, Rita ;
Gyawali, Bishal ;
Jackson, Jeffrey L. ;
Asimakopoulos, Fotis ;
Hari, Parameswaran N. .
JAMA ONCOLOGY, 2018, 4 (03) :343-350
[7]   Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Dimopoulos, M. A. ;
Moreau, P. ;
Terpos, E. ;
Mateos, M., V ;
Zweegman, S. ;
Cook, G. ;
Delforge, M. ;
Hajek, R. ;
Schjesvold, F. ;
Cavo, M. ;
Goldschmidt, H. ;
Facon, T. ;
Einsele, H. ;
Boccadoro, M. ;
San-Miguel, J. ;
Sonneveld, P. ;
Mey, U. .
ANNALS OF ONCOLOGY, 2021, 32 (03) :309-322
[8]   International uniform response criteria for multiple myeloma [J].
Durie, B. G. M. ;
Harousseau, J-L ;
Miguel, J. S. ;
Blade, J. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Dimopoulos, M. ;
Westin, J. ;
Sonneveld, P. ;
Ludwig, H. ;
Gahrton, G. ;
Beksac, M. ;
Crowley, J. ;
Belch, A. ;
Boccadaro, M. ;
Turesson, I. ;
Joshua, D. ;
Vesole, D. ;
Kyle, R. ;
Alexanian, R. ;
Tricot, G. ;
Attal, M. ;
Merlini, G. ;
Powles, R. ;
Richardson, P. ;
Shimizu, K. ;
Tosi, P. ;
Morgan, G. ;
Rajkumar, S. V. .
LEUKEMIA, 2006, 20 (09) :1467-1473
[9]   Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients [J].
Gonzalez-Calle, Veronica ;
Slack, Abigail ;
Keane, Niamh ;
Luft, Susan ;
Pearce, Kathryn E. ;
Ketterling, Rhett P. ;
Jain, Tania ;
Chirackal, Sintosebastian ;
Reeder, Craig ;
Mikhael, Joseph ;
Noel, Pierre ;
Mayo, Angela ;
Adams, Roberta H. ;
Ahmann, Gregory ;
Braggio, Esteban ;
Stewart, A. Keith ;
Bergsagel, P. Leif ;
Van Wier, Scott A. ;
Fonseca, Rafael .
ANNALS OF HEMATOLOGY, 2018, 97 (08) :1453-1462
[10]   The neutrophil to lymphocyte ratio as a novel predictor of asthma and its exacerbation: a systematic review and meta-analysis [J].
Huang, W-J ;
Huang, G-T ;
Zhan, Q-M ;
Chen, J-L ;
Luo, W-T ;
Wu, L-H ;
Wu, L-Y ;
Lu, Z-N ;
Sun, Y-F .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (22) :11719-11728